Journal of Clinical Pathways

In this interview, Puneeth Indurlal, MD, MS, discusses the health-related social needs of patients with cancer, common types of distress reported by patients, and how assessment tools can inform the development of support services. "Knowing that health-related social needs are common within cancer patients' treatment journeys is going to be very important to design appropriate programs or have appropriate resources available. With the top symptoms that patients are facing—whether physical, emotional, or practical problems—it's important to have appropriate systems and resources in place," said Dr Indurlal. Check out the full interview here: https://lnkd.in/esAZecen #JournalOfClinicalPathways #CancerCare #Oncology #AccessSupport #ValueBasedCare

In the second part of this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, cover the US federal government’s role in health care—Medicare, Medicaid, and the Affordable Care Act. They discuss the benefits, challenges, and potential room for improvement in government-sponsored health care in the United States. "My fear, especially with all the new technology stuff, is that if it hasn't been validated, then we're going to wind up falling in love with the technology before we know it's worth anything... We have a lot of learning to do, but I think we can learn together. Validation, veracity, all critical to making this part of how we improve health care in America. And we cannot let that profit mode get in the way," said Dr Kolodziej. Watch the full video here: https://lnkd.in/e69_GV2b #JournalOfClinicalPathways #HealthCare #AI #ValueBasedCare #Oncology #CancerCare

NEW ISSUE ALERT 📢 Check out the latest issue of the Journal of Clinical Pathways! https://lnkd.in/e7PYuSnj Featured stories include: Anna Bolha, et al discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1 pathways were integrated into Flatiron Assist, an electronic health record-embedded clinical decision support tool in OncoEMR. Ray Page, DO, PhD, FACOI, FASCO, describes how congruent solutions for treatment options can be achieved if the objectives of precision medicine and treatment pathways are aligned. Dennis Holmes, MD, et al, explore how clinical pathways can help reduce time to treatment delays while improving health care quality, lowering direct and indirect health care costs, reducing patient financial toxicity, and achieving greater patient, provider, and payer satisfaction. Lee Blansett, MBA, HMP Market Access Insights focuses on provider-implemented pathways in provider organizations and their association with other internal structures and processes within a wide range of organizations providing treatment to patients with cancer. #Journalofclinicalpathways #JCP #Valuebasedcare #CancerCare #HMPMarketAccessInsights #Flatiron #OncoEMR #AmericanOncologyNetwork #Precisionmedicine #EHR

We sat down with Farrukh Awan, MD, University of Texas Southwestern Medical Center, about some of the most promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL). "There are ongoing comparative trials, which are trying determine whether combination time-limited therapy of the two most active compounds—BTK inhibitors and the BPL2 inhibitors—will result in a better outcome for our patients in the long run. I highly recommend all our patients to participate in those trials," said Dr Awan. Check out the full interview here: https://lnkd.in/dG6dua2p #JournalOfClinicalPathways #CLL #ChronicLymphocyticLeukemia #ClinicalTrials #ValueBasedCare

🌟 Featured Session Alert: Journal of Clinical Pathways' Year in Review 🌟 Join us for an insightful session where Winston Wong, PharmD, the Editor-in-Chief of the Journal of Clinical Pathways (JCP), will review the Journal’s most impactful articles from the past year. JCP is renowned for its peer-reviewed education on the development, implementation, and evaluation of clinical pathways. Secure your spot today: 🔗 https://lnkd.in/exHq76da Topics covered will include: - Comparative-effectiveness research - Big data analytics - Methods in clinical pathway development - Optimization of clinical pathway implementation and adherence - Health economics and outcomes research - Patient-centered outcomes - Alternative payment and value-based care models Don't miss this opportunity to stay updated with the latest advancements in clinical pathways. 📅 September 6-8, 2024 📍 Westin Copley Place, Boston, MA 🔗 View the full agenda and expert lineup of speakers: https://lnkd.in/eay3Cnxd #ClinicalPathways #HealthcareInnovation #HealthEconomics #ValueBasedCare #BigData #PatientCenteredOutcomes #ClinicalPathwaysCongress #CancerCareBusinessExchange #DisruptCancerCare

In this interview, Alex Spira, MD, PhD, FACP, FASCO, discussed post-progression results from the phase 3 MARIPOSA-2 trial, which showed that amivantamab plus chemotherapy prolonged time to treatment discontinuation and time to subsequent therapy in patients with EGFR-mutated NSCLC. "We believe this will present a new standard after disease progression on osimertinib," said Dr Spira. Check out the full video here: https://lnkd.in/ebVwQnuu #JournalOfClinicalPathways #NonSmallCellLungCancer #NSCLC #ClinicalTrial 

Did you know only 1 in 5 oncologists currently work in an independent community setting? As practice consolidation rises, it’s crucial to evaluate the industry's response. Join us this fall to assess what measures have been effective, identify what hasn't worked, and find a balance between healthcare providers' goals and business decisions. Our goal is to ensure that patient care quality remains uncompromised by these changes. Don’t miss out on gaining valuable insights to enhance cancer care. Discounted rates end 8/4: https://lnkd.in/e2UiyJa5 📅 September 6-8, 2024 📍 Westin Copley Place, Boston, MA 🔗 View the full agenda and expert lineup of speakers: https://lnkd.in/eay3Cnxd Ronald Barkley, MS, JD #Oncology #PracticeConsolidation #IndependentPractices #HealthcareProviders #PatientCare #HealthcareQuality #ClinicalPathwaysCongress #CancerCareBusinessExchange #HMPMarketAccessInsights #DisruptCancerCare

Don't miss our latest blog post, from Journal of Clinical Pathways Editor-in-Chief Winston Wong: "Our goal is to revolutionize the cancer care arena by breaking down barriers and pushing the boundaries of how we deliver and pay for care." This year’s Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 6-8 in Boston, will bring together industry leaders, health care providers, researchers, payment reform experts, and innovators to discuss advances in oncology care, reimbursement, and alternative payment and business models. Learn more:

🕒 Time is running out! Don't miss your chance to secure early bird rates to join us in Boston on September 6-8. 🏃♀️🏃♂️ Rates expire at midnight on Friday, August 2. Act Now: https://lnkd.in/e2UiyJa5 Join us for an engaging three-day program where you'll have the chance to interact with providers, insurers, technology platforms, pathway providers, and industry experts. Check out the full agenda and lock in your savings today: https://lnkd.in/eay3Cnxd #ClinicalPathways #CancerCare #Oncology #HealthcareEvents #EarlyBird #SaveTheDate #HealthcareInnovation #BostonEvents #HMPMarketAccessInsights #ClinicalPathwaysCongress #CancerCareBusinessExchange #DisruptCancerCare

We spoke with Farrukh Awan, MD, University of Texas Southwestern Medical Center, about some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years. "At some point, we hope to have a strategy that would cure or permanently eliminate the disease in a small subset of our patients. However, it's hard to quantify cures in CLL because the remission period is so long that we have to follow patients for a long period of time to definitively say that the cancer has completely been eliminated and will not come back after stopping therapy," said Dr Awan. Watch the full interview here: https://lnkd.in/dy4v4HJz #JournalOfClinicalPathways #CLL #ChronicLymphocyticLeukemia #CancerCare